Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None20222021202020192018201720162015 Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting 11/05/2019 Poseida Therapeutics Appoints Kerry Ingalls as Chief Operating Officer 10/10/2019 Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma 05/13/2019 Poseida Therapeutics Raises $142 Million in Series C Financing 04/22/2019 Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks 02/13/2019 Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions 01/04/2019 Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting 12/03/2018 Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting 11/29/2018 Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101 11/05/2018 Poseida Therapeutics Appoints Marcy Graham as Vice President, Corporate Affairs 10/09/2018 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 Next page next › Last page last » Displaying 41 - 50 of 84
Year None20222021202020192018201720162015 Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting 11/05/2019 Poseida Therapeutics Appoints Kerry Ingalls as Chief Operating Officer 10/10/2019 Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma 05/13/2019 Poseida Therapeutics Raises $142 Million in Series C Financing 04/22/2019 Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks 02/13/2019 Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions 01/04/2019 Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting 12/03/2018 Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting 11/29/2018 Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101 11/05/2018 Poseida Therapeutics Appoints Marcy Graham as Vice President, Corporate Affairs 10/09/2018 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 Next page next › Last page last » Displaying 41 - 50 of 84
Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting 11/05/2019
Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma 05/13/2019
Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks 02/13/2019
Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions 01/04/2019
Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting 12/03/2018
Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting 11/29/2018
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101 11/05/2018